ADMIDE(Bicalutamide)
Therapeutic class: Androgen Receptor inhibitor
Indication: Combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 Prostate Cancer.
50 mg Tablets
1 mg:- A strip of 10 tablets- 20°C to 25°C (68°F to 77°F), Shelf Life: 2 Years
- As directed by physician
